Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: A systematic review and meta-analysis

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 12, 2010, Pages 2624-2641

  Siller Matula, J M ^a   Jilma, B ^a   Schror K ^b   Christ, G ^c   Huber, K ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c KAISER FRANZ JOSEF HOSPITAL   (Austria)

^d Wilhelminenhospital   (Austria)

Author keywords

Clopidogrel; Death; Gastrointestinal bleeding; Major adverse cardiac events; Myocardial infarction; Proton pump inhibitor; Stent thrombosis

Indexed keywords

CLOPIDOGREL; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; GASTROINTESTINAL HEMORRHAGE; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR ADVERSE CARDIAC EVENT; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STENT THROMBOSIS; SYSTEMATIC REVIEW;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; GASTROINTESTINAL HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TICLOPIDINE; TREATMENT OUTCOME;

EID: 78349244351     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.04049.x     Document Type: Article

References (62)

1. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157: 148. e1-5.
2. Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008; 52: 1557-63.
3. Siller-Matula JM, Christ G, Lang IM, Delle-Karth G, Huber K, Jilma B. Multiple electrode aggregometry predicts stent thrombosis better than the VASP assay. J Thromb Haemost 2010; 8: 351-9.
4. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM, Harrington RA, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Hlatky MA, Kaul S, Lindner JR, Moliterno DJ, Mukherjee D, Schofield RS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52: 1502-17.
5. Siller-Matula JM, Krumphuber J, Jilma B. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular disease. Br J Pharmacol 2009; 159: 502-17.
6. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall JF, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-60.
7. Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, Schomig A, Kastrati A, Von Beckerath N. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101: 714-9.
8. Cuisset T, Frere C, Quilici J, Poyet R, Gaborit B, Bali L, Brissy O, Morange PE, Alessi MC, Bonnet JL. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose. J Am Coll Cardiol 2009; 54: 1149-53.
9. Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, Salazar DE, Winters KJ. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008; 48: 475-84.
10. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116: 2923-32.
11. O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman J, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989-97.
12. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, Henry DA, Kopp A, Mamdani MM. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 713-8.
13. Stanek EJ, Aubert R, Flockhart D, Kreutz RP, Yao J, Breall J, Desta Z, Skaar T, Frueh F, Teagarden J, Epstein R. A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated with Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study. presented at SCAI, Las Vegas 2009:Abstract O-11.
14. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-44.
15. Sarafoff N, Sibbing D, Sonntag U, Schulz S, Schoemig A, Kastrati A. Higher stent thrombosis rate after coronary stenting in patients on dual antiplatelet treatment and concomitant treatment with proton pump inhibitors. Eur Heart J 2009; 30(Suppl.): P150. Abstract 894.
16. Banerjee S, Varghese C, Weideman R, Weideman M, Little BB. Proton pump inhibitors increase the risk of major adverse cardiovascular events in post-PCI patients who are on clopidogrel. Eur Heart J 2009; 30(Suppl.): P92. Abstract P653.
17. Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 2008; 52: 1038-9.
18. Jarai R, Brosovic I, Tentzeris I, Farhan S, Unger G, Huber K. Effects of proton-pump inhibitors on outcome of patients discharged on dual-antiplatelet therapy after percutaneous coronary intervention and stent implantation. Eur Heart J 2009; (Suppl. 30):P98. Abstract P675.
19. Ramirez JF, Selzer F, Chakaprani R, Anderson WD, Lee JS, Smith C, Mulukutla RS, Kip KE, Kelsey SF, Marroquin OC. Proton pump inhibitor and clopidogrel combination is not associated with adverse clinical outcomes after PCI: The NHLBI Dynamic Registry. American College of Cardiology Session/i2 Summit 2009; A27: 2903-7.
20. Zairis M, Patsourakos N, Makrygiannis S, Vogiatzidis C, Gougourela E, Karvounaris S, Ritsatos C, Ampartzidou O, Fakiolas C, Foussas SG. The impact of oral proton pump inhibitors on the effectiveness of combined aspirin and clopidogrel drug therapy during the first year after elective coronary stenting. Eur Heart J 2008; 29(Suppl.): P134. Abstract 934.
21. Gaspar A, Ribeiro S, Nabais S, Rocha S, Azevedo P, Pereira M, Brandao A, Correia A. Proton pump inhibitors in patients treated with aspirin and clopidogrel. Eur Heart J 2009;30 (Suppl.) 444. Abstract 2679.
22. Simon T, Quandalle PH, Machecourt J, Sader R, Ledain L, Bataille V, Brunel PH, Djiane P, Julliard JM, Danchin N. Proton Pump inhibitors and clopidogrel response on cardiovascular major events in patients after acute myocardial infarction. Data from the FAST-MI registry of the french society of cardiology. Eur Heart J 2009; 30(Suppl.): P2121.
23. Bhatt DL. COGENT: A Prospective, Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel. presented at TCT 2009 San Francisco 2009:; Accessed 8 October 2009.
24. Dunn SP, Macaulay TE, Brennan DM, Campbell CL, Charnigo RJ, Smyth SS, Berger PB, Steinhubl SR, Topol EJ. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation 2008;118(A:3999):P815.
25. Biondi-Zoccai GG, Lotrionte M, Abbate A, Testa L, Remigi E, Burzotta F, Valgimigli M, Romagnoli E, Crea F, Agostoni P. Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study. BMJ 2006; 332: 202-9.
26. Wells G, Beaton D, Shea B, Boers M, Simon L, Strand V, Brooks P, Tugwell P. Minimal clinically important differences: review of methods. J Rheumatol 2001; 28: 406-12.
27. Rucker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol 2008; 8: 79.
28. Zairis MN, Tsiaousis GZ, Patsourakos NG, Georgilas AT, Kontos CF, Adamopoulou EN, Vogiatzidis K, Argyrakis SK, Fakiolas CN, Foussas SG. The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting. Can J Cardiol 2010; 26: e54-7.
29. Gupta E, Bansal D, Sotos J, Olden K. Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci 2010; 55: 1964-8.
30. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009; 120: 2322-9.
31. Evanchan J, Donnally MR, Binkley P, Mazzaferri E. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol 2010; 33: 168-71.
32. Ray WA, Murray KT, Griffin MR, Chung CP, Smalley WE, Hall K, Daugherty JR, Kaltenbach LA, Stein CM. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med 2010; 152: 337-45.
33. Stockl KM, Le L, Zakharyan A, Harada AS, Solow BK, Addiego JE, Ramsey SC. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med 2010; 170: 704-10.
34. Sweeny JM, Kini A, Muntner P, Jakkula M, Farkouh M, Sharma S. Mortality associated with proton pump inhibitors following percutaneous coronary interventions with drug eluting stents. Circulation 2009; 120: S936.
35. Torguson R, Chou C, Kaneshige K, Xue Z, Satler L, Kent K, Pichard A, Suddath W, Waksman R. Does proton pump inhibitor use following percutaneous coronary intervention with drug-eluting stents impact clinical outcome? Circulation 2009; 120: S968.
36. Ng FH, Lam KF, Wong SY, Chang CM, Lau YK, Yuen WC, Chu WM, Wong BC. Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy. Digestion 2008; 77: 173-7.
37. Harjai JK, Shenoy C, Orshaw P, Boura J, Rogers G Six-Month Outcomes with or without Proton-Pump Inhibitors after Successful PCI: Insights from the Guthrie PCI Registry. ACC 2010:A2903-07.
38. Charlot MG, Ahlehoff O, Jorgensen CH, Abildstrom SZ, Køber L, Hansen PR, Torp-Pedersen C, Gislason G. Proton Pump Inhibitors are Associated with Cardiovascular Risk Independent of Clopidogrel Use in Patients with Myocardial Infarction: A Nationwide Propensity Score Matched Study. ACC 2010; A1100-273.
39. Oshima S, Noda K, Fukushima H, Nakamura S, Taniguchi I, Kugimiya F, Higa K, Nishijima T, Hanatani S. Pharmacodynamic Effects and Clinical Outcomes of Clopidogrel and Ticlopidine with or without a Proton-pump Inhibitor. ACC 2010 Atlanta A:1021-110.
40. Gaglia MA Jr, Torguson R, Hanna N, Gonzalez MA, Collins SD, Syed AI, Ben-Dor I, Maluenda G, Delhaye C, Wakabayashi K, Xue Z, Suddath WO, Kent KM, Satler LF, Pichard AD, Waksman R. Relation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomes. Am J Cardiol 2010; 105: 833-8.
41. Hall NL, Mathews KD, May HT, Bair TL, Horne BD, Carlquist JF, Lappé DL, Muhlestein JB, Anderson JL. Cardiovascular risk associated with concurrent proton pump inhibitor and clopidogrel therapy: how much? how specific? Circulation 2009; 120: S422.
42. Rossini R, Musumeci G, Lettieri C, Nijaradze T, Biondi Zoccai G, Romano M, Lortkipanidze N, Cicorella N, Gavazzi A, Angiolillo DJ. Prevalence, predictors, and long-term prognosis of discontinuation of oral antiplatelet therapy after DES implantation. Eur Heart J 2009;30(Abstract Suppl.):741 A: P4532.
43. Ching G, Li D, McKay R, Mather J, Lundbye J. Proton pump inhibitors increase major adverse cardiac events among post percutaneous coronary intervention patients on clopidogrel. Circulation 2009; 120: S936-7.
44. Shimomura H, Hokimoto S, Ogawa H, Investigators TK. Clinical outcomes following coronary stenting in Japanese patients with and without proton pump inhibitor. ACC 2010; A:1074-99.
45. Ng FH, Wong SY, Lam KF, Chang CM, Lau YK, Chu WM, Wong BC. Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome. Am J Gastroenterol 2008; 103: 865-71.
46. Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 2010; 31: 810-23.
47. Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthelemy O, Cayla G, Beygui F, Montalescot G. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010; 56: 134-43.
48. Damman K, Jaarsma T, Voors AA, Navis G, Hillege HL, Van Veldhuisen DJ. Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH). Eur J Heart Fail 2009; 11: 847-54.
49. Rasoul S, Ottervanger JP, De Boer MJ, Dambrink JH, Hoorntje JC, Marcel Gosselink AT, Zijlstra F, Suryapranata H, Van't Hof AW. Predictors of 30-day and 1-year mortality after primary percutaneous coronary intervention for ST-elevation myocardial infarction. Coron Artery Dis 2009; 20: 415-21.
50. Shaw JA, Andrianopoulos N, Duffy S, Walton AS, Clark D, Lew R, Sebastian M, New G, Brennan A, Reid C, Ajani AE. Renal impairment is an independent predictor of adverse events post coronary intervention in patients with and without drug-eluting stents. Cardiovasc Revasc Med 2008; 9: 218-23.
51. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A, Kastrati A, Von Beckerath N. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849-56.
52. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009; 119: 237-42.
53. Lemesle G, Delhaye C, Sudre A, Broucqsault D, Rosey G, Bauters C, Lablanche JM. Impact of high loading and maintenance dose of clopidogrel within the first 15-days after percutaneous coronary intervention on patient outcome. Am Heart J 2009; 157: 375-82.
54. Angiolillo DJ, Bernardo E, Sabate M, Jimenez-Quevedo P, Costa MA, Palazuelos J, Hernandez-Antolin R, Moreno R, Escaned J, Alfonso F, Banuelos C, Guzman LA, Bass TA, Macaya C, Fernandez-Ortiz A. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007; 50: 1541-7.
55. Ang L, Palakodeti V, Khalid A, Tsimikas S, Idrees Z, Tran P, Clopton P, Zafar N, Bromberg-Marin G, Keramati S, Mahmud E. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol 2008; 52: 1052-9.
56. Aggarwal A, Dai D, Rumsfeld JS, Klein LW, Roe MT. Incidence and predictors of stroke associated with percutaneous coronary intervention. Am J Cardiol 2009; 104: 349-53.
57. Salustri A, Ciavatti M, Seccareccia F, Palamara A. Prediction of cardiac events after uncomplicated acute myocardial infarction by clinical variables and dobutamine stress test. J Am Coll Cardiol 1999; 34: 435-40.
58. Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006; 4: 2508-9.
59. Siller-Matula J, Schror K, Wojta J, Huber K. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007; 97: 385-93.
60. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008; 392: 1093-108.
61. Khalique SC, Cheng-Lai A. Drug interaction between clopidogrel and proton pump inhibitors. Cardiol Rev 2009; 17: 198-200.
62. Vandenbroucke JP. Commentary: the HRT story: vindication of old epidemiological theory. Int J Epidemiol 2004; 33: 456-7.